A Phase 3 interventional study of Anticoagulants in Hemorrhage, Intracranial Hemorrhages and Bleeding, sponsored by University of Texas at Austin. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by University of Texas at Austin · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Intracranial Hemorrhages with a site in United States — 17 open to participants now, 21 under way, 1 of them phase 3. Intracranial Hemorrhages · United States.
Among the 63 studies in Intracranial Hemorrhages with a site in United States, this one has the largest planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2021, is one of 5 in phase 3, reaches primary completion later than 3 of the 20 other live ones, and was the 38th registered.
211 studies on the registry are indexed under Intracranial Hemorrhages; 62 are open to participants now.
Browse Intracranial Hemorrhages studies →17 of the 63 studies in Intracranial Hemorrhages with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 8 mo–24 mo
Dr. Kerstin de Wit · Sites in United States, Canada
Ages 65+
Ohio State University · Sites in United States
Ages 18+
Christopher P Kellner · Sites in United States
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Intracranial Hemorrhages studies recruiting now, 27 (63%) set no upper age limit and 5 (12%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 6 · Phase 4 7
First in 1987; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,100 is above the median of 87 across 118 interventional studies indexed under Intracranial Hemorrhages.
Median enrollment 50 across the 43 interventional studies, 178 across the 19 observational. Of the 37 that completed or were terminated, 16 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 63 have an industry lead sponsor. The 10 most frequent:
University of Texas at Austin is the lead sponsor of 328 studies on the registry; 79 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
University of Texas at Austin has 1 study filed under Intracranial Hemorrhages — fewer than ten, so there is no comparison to draw.
6 of the studies in Intracranial Hemorrhages with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04229758Phase 3University of Texas at AustinRestarting Anticoagulation After Traumatic Intracranial Hemorrhage | 2026-12 |
| NCT06632587Thomas Jefferson UniversityTiming Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes | 2026-12-01 |
| NCT05361070University of California, San FranciscoNeonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy | 2027-02-28 |
| NCT07738432University of Wisconsin, MadisonNeuro-MoD: Neuroplasticity With Motor Development | 2027-06 |
| NCT06226805Basking Biosciences, Inc.Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 63 studies in Intracranial Hemorrhages with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To identify the optimal interval to restart oral anticoagulation after traumatic intracranial hemorrhage that will minimize thrombotic events and major bleeding by performing a response adaptive randomized (RAR) PROBE clinical trial of restarting in anticoagulant-associated traumatic intracranial hemorrhage patients, comparing restart at 1 week to restart at 2 weeks or at 4 weeks, with a primary composite outcome of major thrombotic events and bleeding.
Primary Outcome: 60-day composite of thromboembolic events, defined as DVT, pulmonary emboli, myocardial infarctions, ischemic strokes and systemic emboli, and bleeding events defined as non-CNS major bleeding events (modified BARC3 or above) and worsening index tICrH or new intracranial hemorrhage (ICrH).
Secondary objectives of this trial include:
Title: Restart tICrH Protocol Synopsis A Prospective Randomized Open Label Blinded Endpoint Response Adaptive Clinical Trial of Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Hemorrhage
Objectives: To identify the optimal interval to restart oral anticoagulation after traumatic intracranial hemorrhage that will minimize thrombotic events and major bleeding by performing a response adaptive randomized (RAR) clinical trial of restarting in anticoagulant-associated traumatic intracranial hemorrhage patients, comparing restart at 1 week to restart at 2 weeks or at 4 weeks, with a primary composite outcome of major thrombotic events and bleeding.
Hypotheses: We hypothesize that restarting an oral anticoagulant at one week after anticoagulant-associated traumatic intracranial hemorrhage, compared to delayed restarting, reduces a composite outcome of major thrombotic events and major bleeding.
Study design Prospective, response adaptive randomized, open-label, blinded end-point (PROBE), 40 center national trial Study population -- Approximately 1100 participants with traumatic intracranial hemorrhage and an indication for Direct Oral Anticoagulant Main inclusion criteria
Main exclusion criteria
Interventions: • The trial will randomize patients with anticoagulant-associated traumatic intracranial hemorrhage to restart DOAC at 1 week or 2 weeks or 4 weeks, using an adaptive randomization algorithm that increases the probability of patients being randomized to treatment arms with lower event rates.
Primary efficacy outcome: A 60-day composite outcome that includes the following clinical events:
A. Bleeding Events Worsening tICrH/new ICrH
1)Hematoma expansion/new ICrH lesion on imaging 2)causing objective change in clinical status and 3)leading to stop of anticoagulation (must include all three).
Extracranial Major bleeding BARC3a or above definition. B. Thrombotic events Venous Thromboembolism (VTE) It is defined as a clinical diagnosis of acute proximal (popliteal and above) deep vein thrombosis or pulmonary embolus confirmed on imaging (compression ultrasound or venogram for DVT, CT angiography, other angiography or ventilation/perfusion scan for PE) by a radiologist qualified to interpret the scans in a timely manner. If the radiologist cannot or does not attest to acute versus chronic thrombus, the Adjudication Committee will make this determination according to its charter.
Myocardial Infarction (MI) Fourth Universal Definition of Myocardial Infarction.
Stroke New focal neurologic deficit consistent with ischemic stroke and confirmed by a stroke specialist or brain imaging. Brain imaging must be performed but need not be positive if the stroke specialist (neurology, neurosurgery or internal medicine) deems a clinically probable stroke.
Systemic Embolism A clinical diagnosis of extracranial infarction associated with likely thromboembolism and documented by angiography or surgery in the absence of atherosclerotic occlusion.
Cardiovascular death non bleeding Death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular procedures, and death from other cardiovascular causes 45. A patient who has both this outcome and another thrombotic outcome will only be counted once as this outcome.
Secondary outcomes: Modified Rankin Scale and Disability Rating Scale
Safety outcomes: Incorporated in composite as thrombotic and bleeding events
Statistical analysis: All interim and final analyses will be conducted on the primary outcome, the composite 60-day outcome of thromboembolic events and recurrent hemorrhage. Both thrombotic and bleeding outcomes will be modeled as a function of the three treatment arms in a dose (time)/response (events composite) model. Two Bernoulli models will be used to estimate thromboembolism and recurrent hemorrhage. Each of the rates for the Bernoulli values by dose are θd and δd for thromboembolism and recurrent hemorrhage respectively. These rates are combined to provide a utility function Ud=-θd-δd, so higher values of Ud correspond to the better dose to establish specifically whether at a week is best and generally whether earlier is better than later.
Sample size: 1100
Clinical sites: Approximately 40 trauma center clinical sites in the US.
Recruitment period: Approximately 60 months
Follow-up period: Participants will be followed weekly for 60 days, the study end date.
Special procedures: N/A
Coordinating centers: Seton Dell Medical School Stroke Institute, Coalition for National Trauma Research, Kansas University Medical Center
Sponsor: Seton Dell Medical School Stroke Institute
211 studies on the registry are indexed under Intracranial Hemorrhages; 62 are open to participants now.
This study's planned enrollment of 1,100 is above the median of 87 across 118 interventional studies indexed under Intracranial Hemorrhages.
Browse Intracranial Hemorrhages studies →University of Texas at Austin is the lead sponsor of 328 studies on the registry; 79 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Compared within Intracranial Hemorrhages, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hemorrhage. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Entry into the trial is primarily driven pragmatically by clinician intent to restart a Direct Oral Anticoagulant (DOAC) after anticoagulant-associated traumatic intracranial hemorrhage and equipoise concerning restart of anticoagulation at the specified time intervals. DOAC will be at label dose with label adjustments for . DOAC will be at continuation dose, i.e. not initial therapy high doses in the setting of VTE.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
Drug: Anticoagulants
Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
Drug: Anticoagulants
Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
Drug: Anticoagulants
DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
60 Day Composite of Thrombotic and Bleeding Events
Composite of Thrombotic events, defined as DVT, PE, MI, Ischemic Strokes, and systemic emboli, cardiovascular death along with bleeding events defined as non-CNS major bleeding, worsening index tICrH, or new intracranial hemorrhage.
Time frame: 60 days following index bleeding event
60 Day Disability Rating Scale (1-29 with 29 being worse)
DRS is a scale to measure disability after an injury
Time frame: 60 days following index bleeding event
60 Day Modified Rankin Scale (1-6 with 6 being worse)
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.
Time frame: 60 days following index bleeding event
Standard Gamble Patient Reported utilities for endpoints
Performed prior to randomization and immediately after each endpoint
Time frame: pre-randomization and after endpoints
Plan to share: Yes — Sharing of data generated by this project is an essential part of our proposed activities. Following study completion, the DCC staff will follow National Trauma Research Repository (NTRR) and NHLBI's Biologic Specimen and Data Repository Information Coordinating Center (BioLLINCC) policies to upload the study's final de-identified data set, supporting documentation (data dictionary, protocol, consent form, data analysis plans) and any manuscripts. The final data set will be a csv file upload that is consistent with the NTRR data element attributes and characteristics.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: After publication of primary manuscript
No publications or documents are linked to this record.
Start is estimated for Oct 2021; primary completion for Dec 2026, 62 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas at Austin →